Relative sensory sparing in the diabetic foot implied through vibration testing

Todd O’Brien, DPM¹* and Joseph Kareem, MS²

¹Health Access Network, Lincoln, ME; ²Independent Consultant

Background: The dorsal aspect of the hallux is often cited as the anatomic location of choice for vibration testing in the feet of diabetic patients. To validate this preference, vibration tests were performed and compared at the hallux and 5th metatarsal head in diabetic patients with established neuropathy.

Methods: Twenty-eight neuropathic, diabetic patients and 17 non-neuropathic, non-diabetic patients underwent timed vibration testing (TVT) with a novel 128 Hz electronic tuning fork (ETF) at the hallux and 5th metatarsal head.

Results: TVT values in the feet of diabetic patients were found to be reduced at both locations compared to controls. Unexpectedly, these values were significantly lower at the hallux (P < 0.001) compared to the 5th metatarsal head.

Conclusion: This study confirms the hallux as the most appropriate location for vibration testing and implies relative sensory sparing at the 5th metatarsal head, a finding not previously reported in diabetic patients.

Keywords: diabetic foot; diabetes mellitus; diabetic polyneuropathy; diabetes-related complications; neurological examination; sural nerve

Received: 30 April 2013; Revised: 25 August 2013; Accepted: 26 August 2013; Published: 16 September 2013

Diabetic peripheral neuropathy (DPN) has been established as an essential precursor leading to foot ulcers, infections, and lower extremity amputation (1). Effective clinical screening for DPN and implementation of preventative strategies designed to reduce complications leading to limb loss have been acknowledged as critical aspects in the care of diabetic patients (2, 3).

One of the most frequently used neurological screening tools for DPN is the 128 Hz tuning fork. The dorsal aspect of the distal phalanx of the hallux has long been cited as the anatomic location of choice for vibration testing with the tuning fork (4–8). Alternatively, some researchers have advocated vibration testing at other sites, including the 5th metatarsal head (9, 10). This study was undertaken to validate the choice of the hallux as the preferred site for vibration testing in the diabetic foot.

Methods
To test this recommendation, tuning fork testing was performed at the hallux and 5th metatarsal head in diabetic patients with neuropathy (neuropathy diagnosis was established by conventional neurological testing). Standardization of testing between test subjects and anatomic sites was improved through the use of a novel 128 Hz electronic tuning fork (ETF) (11). This device electronically reproduces the same vibration output and decay rate as the traditional tuning fork. An integrated timer facilitates performance of timed vibration tests (TVTs), which have been shown to be a valid method of detecting neuropathy (12, 13). TVT values at the hallux and 5th metatarsal head were collected and analyzed.

Fifty-five patients were recruited on a rolling basis over a 6-month period for participation in the study at the Health Access Network, Lincoln, ME (Table 1). Criteria included being older than 18 years. Exclusion criteria included foot amputation, open foot ulcers, or foot infection. Diabetes diagnosis was determined by medical history. For the purposes of this study, patients were further subdivided into a diabetic, neuropathic group and a non-diabetic, non-neuropathic group. Comparison between these two groups was then made with regard to vibratory sensation. The study protocol was approved by the institutional review board administered by Portable Ethics IRB of Windham, ME. Written informed consent was obtained from all participants in this study.

To diagnose neuropathy, each test subject underwent testing with a 5.07/10 g Semmes-Weinstein monofila-ment test (SWMT) (Touch-Test; North Coast Medical, Morgan Hill, CA), biothesiometer (Biomedical Instruments, Newbury, OH), sharp/dull discrimination test, and ETF (O’Brien Medical, Orono, ME). An abnormal result
from any one of the conventional tests (SWMT, biothesiometer, sharp/dull discrimination test) qualified a test subject as neuropathic. Each test was administered in a treatment room with an ambient temperature of 70–72°F. Test subjects had their socks removed for 5–10 min prior to testing.

Specific testing protocols were as follows

**SWMT**: The accuracy of monofilaments was assessed daily with a digital scale prior to testing. Monofilaments registering beyond ±5% of the desired 10 g of pressure were not used. Standard technique (2) was used when applying the monofilaments to the plantar aspects of the 1st and 5th digits. Test subjects, with eyes closed, would verbally indicate perception of the monofilament touch by saying ‘yes’. Lack of an expected response at any location constituted an abnormal reading.

**Biothesiometer**: The biothesiometer was set at the 25-v level and applied to the dorsal aspect of the distal phalanx of the hallux and the dorsal aspect of the 5th metatarsal head. Test subjects would verbally indicate if they perceived vibrations with a ‘yes’ or ‘no’. Lack of patient perception at any location constituted an abnormal reading.

**Sharp/Dull Discrimination Test**: A sharply cut monofilament imparting 60 g, ±5% was applied for sharp touch. A monofilament terminating in a blunt polyisoprene tip imparting 225 g, ±5% was applied for dull touch. Standard technique (2) was used when applying the monofilaments to the plantar aspects of the 1st and 5th digits. Test subjects, with eyes closed, would indicate if they perceived the touch of the instrument as either ‘sharp’ or ‘dull’. Incorrect responses at any location constituted an abnormal reading.

**ETF**: The contact point of the ETF was applied to the dorsal aspect of the distal phalanx of the hallux and the dorsal aspect of the 5th metatarsal head (Fig. 1). The device was activated, simultaneously starting the vibrations and integrated timer. Test subjects would verbally indicate if they perceived vibrations with a ‘yes’ or ‘no’. Those indicating ‘no’ were recorded as 0 sec elapsed time. Those indicating ‘yes’ were asked to state when the vibrations subsided beyond their perception by saying ‘now’. At this point, the device was stopped and the elapsed time was recorded. In addition to neurological testing, patient demographic and diabetes history were also collected. A paired $t$-test was done on the data from the ETF to determine if there was any difference in sensitivity between the hallux and 5th metatarsal head in participating patient feet. No transformation of patient data was necessary to meet the assumptions of normality. Normality was assessed by examining skewness, kurtosis, and the Shapiro-Wilk W statistic.

**Results**

TVT values from 45 of the 55 patients examined are presented in these results (Table 1). Twenty-eight met the criteria for inclusion in the diabetic, neuropathic group, and 17 met the criteria for inclusion in the non-diabetic, non-neuropathic group. Other characteristics of these patient groups are shown in Table 1.

Table 1. Patient demographics

| Variable          | Diabetic, neuropathic patients | Non-diabetic, non-neuropathic patients |
|-------------------|--------------------------------|----------------------------------------|
| N                 | 28                             | 17                                     |
| Male (%)          | 16 (57.1)                      | 3 (17.6)                               |
| AGE (years)       |                                |                                        |
| Mean ± SD         | 64.6 ± 12.3                    | 53.2 ± 20.1                            |
| Median            | 64.0                           | 57.0                                   |
| Range             | 32–88                          | 20–83                                  |

Fig. 1. The ETF applied to the hallux.
Discussion
In agreement with current clinical guidelines, the results from this study indicate that the dorsal aspect of the distal phalanx of the hallux is an appropriate location for vibration testing in diabetic patients. Unexpectedly, TVT values were found to be significantly longer at the 5th metatarsal head when compared to the hallux. This finding suggests relatively slower progression of DPN at the 5th metatarsal head. Supporting this conclusion are several studies comparing the electrodiagnostic sensitivity of the sural nerve (afferent to the 5th metatarsal head) versus the medial plantar nerve (afferent to the hallux). This occurrence implies more rapid progression of neuropathy at the hallux, which should provide clinicians with a high level of confidence that this is the optimal location for vibration testing in the diabetic foot.

Table 2. An ETF comparison of sensitivity at the hallux versus the 5th metatarsal head for diabetic patients with neuropathy and non-diabetic patients

| Variable                     | Diabetic, neuropathic patients | Non-diabetic, non-neuropathic patients |
|------------------------------|--------------------------------|---------------------------------------|
| N (feet examined)            | 54*                            | 34                                    |
| Hallux Mean ETF (sec)        | 3.57                           | 11.76                                 |
| 5th MTh Mean ETF (sec)       | 5.99                           | 12.19                                 |
| Paired Test (hallux – 5th MTh) |                                |                                       |
| Mean difference (sec)        | −2.42                          | −0.43                                 |
| SD (sec)                     | 5.17                           | 4.18                                  |
| P                            | 0.001                          | 0.556                                 |

*Individual feet were treated as independent, statistical elements for the purposes of this study. Data were erroneously not collected on 2 feet from two different patients. The resultant data set from the 28 diabetic, neuropathic patients therefore yielded only 54 feet.

In particular, Sylantiev et al. compared nerve conduction velocities at the sural and medial plantar nerves in diabetic patients with and without symptoms of distal symmetrical polyneuropathy (DSP) (14). It was found that the medial plantar nerve was a more sensitive choice for diagnosing DSP than the sural (90 vs. 55% sensitivity). It was noted that this finding was contrary to the traditional recommendation of using the sural nerve for electrodiagnostic testing of DSP. The authors concluded that the medial plantar nerve provided a higher diagnostic yield and advocated for preferential testing of this nerve. Similarly, others have independently confirmed that electrodiagnostic testing of the medial plantar nerve provides increased diagnostic sensitivity in diabetic patients when compared to the sural (15–18). Further research on this topic appears warranted given the widespread clinical reliance on electrodiagnostic testing of the sural nerve in a variety of neurological disorders.

One limitation of this study was the individual patient population derived from a single physician practice. Although statistically significant findings were clearly evident, a meta-analysis would serve to confirm our results. Additionally, clinical data collection was carried out by one author who was not blinded to the results of the conventional neurological screening tests (biothesiometer, SWMT and sharp/dull discrimination test) or the patient’s diabetes status.

Another limiting factor was the omission of vibration testing at the plantar aspect of the hallux (i.e. the pulp of the toe). This site has also been advocated by researchers but never directly compared to the dorsal site (2, 19). Although vibrations transmitted through the hallux do stimulate dorsal and plantar mechanoreceptors, it is possible that the plantar site is a more sensitive location for identifying neuropathy. The choice of this alternative location is also supported by the recent focus on the medial plantar nerve in electrodiagnostic research. Inclusion of the plantar hallux site in this study could have provided guidance on this question.

The fact that a unique prototype was used in this study may also be a limiting factor. Although the ETF was designed to replicate the output of a traditional tuning fork, there could be subtle differences between the two. It is not clear if these differences are clinically significant. Additionally, the reproducible vibrations created by the device likely mitigated significant variation between tests.

In conclusion, evidence of relative sensory sparing in diabetic patients with DPN was found when comparing vibratory sensation at the hallux and 5th metatarsal head. This finding, implying more rapid progression of neuropathy at the hallux, should provide clinicians with a high level of confidence that this is the optimal location for vibration testing in the diabetic foot.
Acknowledgements

The authors thank the patients of the Health Access Network for their enthusiastic participation in this study.

Conflict of interest and funding

The primary author (TO) is the founder of O’Brien Medical, LLC and owns all rights to the electronic tuning fork (ETF) used in this study. Subsequent future commercialization of the ETF may financially benefit the author. This study was jointly funded by the Maine Technology Institute and O’Brien Medical, LLC.

Contribution statement

TO designed and conducted the study and wrote the manuscript, JK assisted with the study design, performed statistical analysis and wrote the manuscript. TO is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. American Diabetes Association, Clinical Practice Recommendations. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: S11–61.
2. Boulton A, Armstrong D, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment. Diabetes Care 2008; 31: 1679–85.
3. Pham H, Armstrong DG, Harvey C, Harkless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000; 23: 606–11.
4. Gin H, Rigalleau V, Baillet L, Rabemanantsoa C. Comparison between monofilament, tuning fork and vibration perception tests for screening patients at risk of foot complication. Diabetes Metab 2002; 28: 457–61.
5. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001; 54: 115–28.
6. Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork. Diabetes Care 2005; 28: 2201–5.
7. Campbell WW, DeJong RN, Haerer AF. DeJong’s the neurological examination. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
8. International Working Group on the Diabetic Foot, Consensus Guidelines. Available from: http://iwgdf.org/consensus/diabetic-neuropathy/ [cited 4 August 2013]
9. Bracewell N, Game F, Jeffcoate W, Scammell BE. Clinical evaluation of the VibraTip: a new device in the assessment of peripheral sensory neuropathy in diabetes. Diabet Med 2012; 29: 1553–5.
10. William G, Gill JS, Aber V, Mather HM. Variability in vibration perception threshold among sites: a potential source of error in biothesiometry. British Med J 1988; 296: 233–5.
11. O’Brien T, Kareem J. An initial evaluation of a proof-of-concept 128 Hz electronic tuning fork in the detection of peripheral neuropathy. J Am Podiatr Med Assoc, in press.
12. Botez SA, Liu G, Logigian E, Herrmann DN. Is the bedside timed vibration test reliable? Muscle Nerve 2009; 39: 221–3.
13. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250–6.
14. Sylantiev C, Schwartz R, Chapman J, Buchman A. Medial plantar nerve testing facilitates identification of polyneuropathy. Muscle Nerve 2008; 38: 1595–8.
15. Uluc K, Isak B, Borucu D, Temucin C, Cetinkaya Y, Koytak P, et al. Medial plantar and dorsal sural nerve conduction studies increase the sensitivity in the detection of neuropathy in diabetic patients. Clin Neurophysiol 2008; 119: 880–5.
16. Altun Y, Demirkol A, Tumay Y, Ekmekci K, Unsal I, Koyluoglu A, et al. The medial plantar and medial peroneal cutaneous nerve conduction studies for diabetic polyneuropathy. Neurol Sci 2011; 32: 849–54.
17. Loseth S, Nebuchennykh M, Stålberg E, Mellgren S. Medial plantar nerve conduction studies in healthy controls and diabetics. Clin Neurophysiol 2007; 118: 1155–61.
18. An JY, Park MS, Kim JS, Shon YM, Lee SJ, Kim YI, et al. Comparison of diabetic neuropathy symptom score and medial plantar sensory nerve conduction studies in diabetic patients showing normal routine nerve conduction studies. Inter Med 2008; 47: 1395–8.
19. Thomson FJ, Masson EA, Boulton AJ. Quantitative vibration perception testing in elderly people: an assessment of variability. Age and Ageing 1992; 21: 171–4.

Todd O’Brien
Health Access Network
175 West Broadway
Lincoln, ME 04457
Email: tobrien@obimed.com

*Todd O’Brien

Citation: Diabetic Foot & Ankle 2013, 4, 21278 - http://dx.doi.org/10.3402/dfa.v4i0.21278